CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day scheduleWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (9)


Name (Synonyms) Correlation
drug1849 Placebo on a 0- and 14-day schedule Wiki 1.00
drug1380 Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki 1.00
drug1057 High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki 1.00
drug2407 T3 solution for injection Wiki 1.00
drug1381 Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.71
drug1058 High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.71
drug1850 Placebo on a 0- and 28-day schedule Wiki 0.71
drug1458 Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.71
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years

This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.

NCT04412538 COVID-19 Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Biological: Placebo on a 0- and 28-day schedule Biological: Placebo on a 0- and 14-day schedule

Primary Outcomes

Description: Occurence of adverse reactions/events after vaccination

Measure: Adverse reactions/events rate

Time: 7 days after vaccination

Description: Occurence of adverse reactions/events after vaccination

Measure: Adverse reactions/events rate

Time: 28 days after vaccination

Description: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14

Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)

Time: 14 days after the second vaccination

Description: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28

Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Description: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14

Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)

Time: 14 days after the second vaccination

Description: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28

Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Secondary Outcomes

Description: Occurence of Serious adverse events after vaccination

Measure: Serious adverse events

Time: 12 months after the second vaccination

Description: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14

Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)

Time: 7, 14 and 28 days after the second vaccination

Description: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14

Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)

Time: 14 and 28 days after the second vaccination

Description: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14

Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)

Time: 7, 14 and 28 days after the second vaccination

Description: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14

Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)

Time: 14 and 28 days after the second vaccination

Description: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28

Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)

Time: 7 and 28 days after the second vaccination

Description: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28

Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Description: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28

Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)

Time: 7 and 28 days after the second vaccination

Description: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28

Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Description: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14

Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)

Time: 14 days after the second vaccination

Description: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14

Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)

Time: 14 days after the second vaccination

Description: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28

Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Description: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28

Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Other Outcomes

Description: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14

Measure: Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)

Time: 7, 14 and 28 days after the second vaccination

Description: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14

Measure: Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)

Time: 14 and 28 days after the second vaccination

Description: Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,14

Measure: Level of anti-N protein antibodies Phase Ia (Day 0, 14 schedule)

Time: 7, 14 and 28 days after the second vaccination

Description: Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,14

Measure: Level of anti-N protein antibodies Phase IIa (Day 0, 14 schedule)

Time: 14 and 28 days after the second vaccination

Description: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28

Measure: Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)

Time: 7 and 28 days after the second vaccination

Description: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28

Measure: Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Description: Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,28

Measure: Level of anti-N protein antibodies Phase Ia (Day 0, 28 schedule)

Time: 7 and 28 days after the second vaccination

Description: Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,28

Measure: Level of anti-N protein antibodies Phase IIa (Day 0, 28 schedule)

Time: 28 days after the second vaccination

Description: Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase Ia immunization schedules

Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (both schedules)

Time: 3, 6, 9 and 12 months after the second vaccination

Description: Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase IIa immunization schedules

Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (both schedules)

Time: 6 and 12 months after the second vaccination

Description: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase Ia immunization schedules

Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (both schedules)

Time: 3, 6, 9 and 12 months after the second vaccination

Description: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase IIa immunization schedules

Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (both schedules)

Time: 6 and 12 months after the second vaccination

Description: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,14

Measure: Cellular immune responses Phase Ia (Day 0, 14 schedule)

Time: 7, 14 and 28 days after the second vaccination

Description: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,14

Measure: Cellular immune responses Phase IIa (Day 0, 14 schedule)

Time: 14 and 28 days after the second vaccination

Description: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,28

Measure: Cellular immune responses Phase Ia (Day 0, 28 schedule)

Time: 7 and 28 days after the second vaccination

Description: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,28

Measure: Cellular immune responses Phase IIa (Day 0, 28 schedule)

Time: 28 days after the second vaccination


No related HPO nodes (Using clinical trials)